{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:25:13Z","timestamp":1787009113420,"version":"build-2736575974"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T00:00:00Z","timestamp":1643155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Japanese Ministry of Education, Science and Culture and Kenzo Suzuki Memorial Medical Science Applications Foundation","award":["16390422"],"award-info":[{"award-number":["16390422"]}]},{"name":"Japanese Ministry of Education, Science and Culture and Kenzo Suzuki Memorial Medical Science Applications Foundation","award":["19390385"],"award-info":[{"award-number":["19390385"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although boron neutron capture therapy has shown excellent survival data, previous studies have shown an increase in radiation necrosis against recurrent malignant glioma. Herein, we proposed that bevacizumab may reduce radiation injury from boron neutron capture therapy by re-irradiation. We evaluated the efficacy and safety of a boron neutron capture therapy and add-on bevacizumab combination therapy in patients with recurrent malignant glioma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with recurrent malignant glioma were treated with reactor-based boron neutron capture therapy. Treatment with bevacizumab (10\u00a0mg\/kg) was initiated 1\u20134\u00a0weeks after boron neutron capture therapy and was administered every 2\u20133\u00a0weeks until disease progression. Initially diagnosed glioblastomas were categorized as primary glioblastoma, whereas other forms of malignant glioma were categorized as non-primary glioblastoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-five patients (14 with primary glioblastoma and 11 with non-primary glioblastoma) were treated with boron neutron capture therapy and add-on bevacizumab. The 1-year survival rate for primary glioblastoma and non-primary glioblastoma was 63.5% (95% confidence interval: 33.1\u201383.0) and 81.8% (95% confidence interval: 44.7\u201395.1), respectively. The median overall survival was 21.4\u00a0months (95% confidence interval: 7.0\u201336.7) and 73.6\u00a0months (95% confidence interval: 11.4\u201377.2) for primary glioblastoma and non-primary glioblastoma, respectively. The median progression-free survival was 8.3\u00a0months (95% confidence interval: 4.2\u201312.1) and 15.6\u00a0months (95% confidence interval: 3.1\u201329.8) for primary glioblastoma and non-primary glioblastoma, respectively. Neither pseudoprogression nor radiation necrosis were identified during bevacizumab treatment. Alopecia occurred in all patients. Six patients experienced adverse events \u2265grade 3.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Boron neutron capture therapy and add-on bevacizumab provided a long overall survival and a long progression-free survival in recurrent malignant glioma compared with previous studies on boron neutron capture therapy alone. The add-on bevacizumab may reduce the detrimental effects of boron neutron capture therapy, including pseudoprogression and radiation necrosis. Further studies of the combination therapy with a larger sample size and a randomized controlled design are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyac004","type":"journal-article","created":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T07:20:06Z","timestamp":1641885606000},"page":"433-440","source":"Crossref","is-referenced-by-count":25,"title":["Boron neutron capture therapy and add-on bevacizumab in patients with recurrent malignant glioma"],"prefix":"10.1093","volume":"52","author":[{"given":"Motomasa","family":"Furuse","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka 569-8686, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Kawabata","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka 569-8686, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Wanibuchi","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka 569-8686, Japan"},{"name":"Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka 569-8686, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Shiba","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka 569-8686, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka 569-8686, Japan"},{"name":"Cerebrospinal center, Shiroyama Hospital, Habikino, Osaka 583-0872, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuko","family":"Kondo","sequence":"additional","affiliation":[{"name":"Institute for Integrated Radiation and Nuclear Science, Kyoto University, Kumatori, Osaka 590-0494, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Institute for Integrated Radiation and Nuclear Science, Kyoto University, Kumatori, Osaka 590-0494, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Sakurai","sequence":"additional","affiliation":[{"name":"Institute for Integrated Radiation and Nuclear Science, Kyoto University, Kumatori, Osaka 590-0494, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Cerebrospinal center, Shiroyama Hospital, Habikino, Osaka 583-0872, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Ono","sequence":"additional","affiliation":[{"name":"Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka 569-8686, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8056-1016","authenticated-orcid":false,"given":"Shin-Ichi","family":"Miyatake","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka 569-8686, Japan"},{"name":"Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka 569-8686, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,1,26]]},"reference":[{"key":"2022050521430580000_ref1","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1212\/01.wnl.0000345668.03039.90","article-title":"Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience","volume":"72","author":"Nghiemphu","year":"2009","journal-title":"Neurology"},{"key":"2022050521430580000_ref2","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","article-title":"Lomustine and bevacizumab in progressive glioblastoma","volume":"377","author":"Wick","year":"2017","journal-title":"New Engl J Mmed"},{"key":"2022050521430580000_ref3","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s11060-019-03328-3","article-title":"Fractionated stereotactic radiosurgery for malignant gliomas: comparison with single session stereotactic radiosurgery","volume":"145","author":"Choi","year":"2019","journal-title":"J Neurooncol"},{"key":"2022050521430580000_ref4","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1002\/cncr.23402","article-title":"Efficacy of stereotactic radiosurgery as a salvage treatment for recurrent malignant gliomas","volume":"112","author":"Kong","year":"2008","journal-title":"Cancer"},{"key":"2022050521430580000_ref5","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/1097-0142(19940815)74:4&lt;1342::aid-cncr2820740426&gt;3.0.co;2-y","article-title":"Stereotactic radiosurgery for recurrent gliomas","volume":"74","author":"Chamberlain","year":"1994","journal-title":"Cancer"},{"key":"2022050521430580000_ref6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s11060-008-9699-x","article-title":"Survival benefit of boron neutron capture therapy for recurrent malignant gliomas","volume":"91","author":"Miyatake","year":"2009","journal-title":"J Neurooncol"},{"key":"2022050521430580000_ref7","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1200\/JCO.2006.08.1661","article-title":"Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials","volume":"25","author":"Carson","year":"2007","journal-title":"J Clin Oncol"},{"key":"2022050521430580000_ref8","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1158\/0008-5472.CAN-08-2345","article-title":"L-amino acid transporter-1 and boronophenylalanine-based boron neutron capture therapy of human brain tumors","volume":"69","author":"Detta","year":"2009","journal-title":"Cancer Res"},{"key":"2022050521430580000_ref9","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1227\/01.neu.0000316018.51292.19","article-title":"Enhanced tumor growth elicited by L-type amino acid transporter 1 in human malignant glioma cells","volume":"62","author":"Kobayashi","year":"2008","journal-title":"Neurosurgery"},{"key":"2022050521430580000_ref10","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.3171\/jns.2005.103.6.1000","article-title":"Modified boron neutron capture therapy for malignant gliomas performed using epithermal neutron and two boron compounds with different accumulation mechanisms: an efficacy study based on findings on neuroimages","volume":"103","author":"Miyatake","year":"2005","journal-title":"J Neurosurg"},{"key":"2022050521430580000_ref11","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/neuonc\/not020","article-title":"Bevacizumab treatment of symptomatic pseudoprogression after boron neutron capture therapy for recurrent malignant gliomas. Report of 2 cases","volume":"15","author":"Miyatake","year":"2013","journal-title":"Neuro Oncol"},{"key":"2022050521430580000_ref12","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/j.ijrobp.2009.12.061","article-title":"Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system","volume":"79","author":"Levin","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2022050521430580000_ref13","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1093\/nop\/npv064","article-title":"A prospective, multicentre, single-arm clinical trial of bevacizumab for patients with surgically untreatable, symptomatic brain radiation necrosis (dagger)","volume":"3","author":"Furuse","year":"2016","journal-title":"Neuro Oncol Pract"},{"key":"2022050521430580000_ref14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.radonc.2019.06.009","article-title":"Bevacizumab reduces toxicity of reirradiation in recurrent high-grade glioma","volume":"138","author":"Fleischmann","year":"2019","journal-title":"Radiother Oncol"},{"key":"2022050521430580000_ref15","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2176\/nmc.oa.2018-0111","article-title":"Boron neutron capture therapy combined with early successive bevacizumab treatments for recurrent malignant gliomas - a pilot study","volume":"58","author":"Shiba","year":"2018","journal-title":"Neurol Med Chir"},{"key":"2022050521430580000_ref16","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022050521430580000_ref17","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11060-013-1337-6","article-title":"The role of radiotherapy in the management of progressive glioblastoma: a systematic review and evidence-based clinical practice guideline","volume":"118","author":"Ryu","year":"2014","journal-title":"J Neurooncol"},{"key":"2022050521430580000_ref18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11060-018-03064-0","article-title":"Re-irradiation for recurrent glioblastoma (GBM): a systematic review and meta-analysis","volume":"142","author":"Kazmi","year":"2019","journal-title":"J Neurooncol"},{"key":"2022050521430580000_ref19","doi-asserted-by":"publisher","first-page":"652646","DOI":"10.3389\/fonc.2021.652646","article-title":"CyberKnife for recurrent malignant gliomas: a systematic review and meta-analysis","volume":"11","author":"De Maria","year":"2021","journal-title":"Front Oncol"},{"key":"2022050521430580000_ref20","doi-asserted-by":"publisher","first-page":"vdab052","DOI":"10.1093\/noajnl\/vdab052","article-title":"Systematic review and network meta-analysis of the efficacy of existing treatments for patients with recurrent glioblastoma","volume":"3","author":"Schritz","year":"2021","journal-title":"Neuro Oncol Adv"},{"key":"2022050521430580000_ref21","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/j.ijrobp.2010.12.074","article-title":"Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas","volume":"82","author":"Cuneo","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2022050521430580000_ref22","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1007\/s00701-021-04794-3","article-title":"Radiotherapy versus combination radiotherapy-bevacizumab for the treatment of recurrent high-grade glioma: a systematic review","volume":"163","author":"Kulinich","year":"2021","journal-title":"Acta Neurochir"},{"key":"2022050521430580000_ref23","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/jjco\/hys231","article-title":"Bevacizumab treatment for symptomatic radiation necrosis diagnosed by amino acid PET","volume":"43","author":"Furuse","year":"2013","journal-title":"Jpn J Clin Oncol"},{"key":"2022050521430580000_ref24","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/neuros\/nyx369","article-title":"Phase I trial of radiosurgery dose escalation plus bevacizumab in patients with recurrent\/progressive glioblastoma","volume":"83","author":"Abbassy","year":"2018","journal-title":"Neurosurgery"},{"key":"2022050521430580000_ref25","doi-asserted-by":"publisher","first-page":"vdab067","DOI":"10.1093\/noajnl\/vdab067","article-title":"Accelerator-based BNCT for patients with recurrent glioblastoma: a multicenter phase II study","volume":"3","author":"Kawabata","year":"2021","journal-title":"Neuro Oncol Adv"},{"key":"2022050521430580000_ref26","doi-asserted-by":"crossref","DOI":"10.3390\/biology10040334","article-title":"Salvage boron neutron capture therapy for malignant brain tumor patients in compliance with emergency and compassionate use: evaluation of 34 cases in Taiwan","volume":"10","author":"Chen","year":"2021","journal-title":"Biology"},{"key":"2022050521430580000_ref27","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13014-021-01767-9","article-title":"Current status and recent advances in reirradiation of glioblastoma","volume":"16","author":"Minniti","year":"2021","journal-title":"Radiat Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/52\/5\/433\/43556263\/hyac004.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/52\/5\/433\/43556263\/hyac004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T17:49:26Z","timestamp":1651772966000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/52\/5\/433\/6515543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,26]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,1,26]]},"published-print":{"date-parts":[[2022,5,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyac004","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-930901\/v1","asserted-by":"object"}]},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5]]},"published":{"date-parts":[[2022,1,26]]}}}